Strongbridge Biopharma PLC (SBBP)
(Delayed Data from NSDQ)
$3.47 USD
-0.19 (-5.19%)
Updated May 3, 2019 04:00 PM ET
After-Market: $3.49 (%) 5:22 PM ET
NA Value NA Growth NA Momentum NA VGM
View All Zacks #1 Ranked Stocks
Brokerage Reports
0 items in cart
[SBBP]
Reports for Purchase
Showing records 1 - 20 ( 46 total )
Industry: Medical - Biomedical and Genetics
Price: 25.00
Industry: Medical - Biomedical and Genetics
Termination of Coverage With Announced Acquisition
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Price: 10.00
Industry: Medical - Biomedical and Genetics
Two Shots on Goal - KEVEYIS Traction Complimented by RECORLEV NDA
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Price: 25.00
Industry: Medical - Biomedical and Genetics
RECORLEV NDA Backed By LOGICS and SONICS, As KEVEYIS Delivers
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Price: 25.00
Industry: Medical - Biomedical and Genetics
KEVEYIS Maintains Momentum; RECORLEV NDA Remains On Track for 1Q21
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Price: 25.00
Industry: Medical - Biomedical and Genetics
All Eyes on Recorlev NDA Submission in 1Q21; Reit Buy and Lowering PT to $10
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Price: 25.00
Industry: Medical - Biomedical and Genetics
LOGIC Delivers Positive Results in Line With Prior Phase 3 SONICS Study; Reit Buy and $18 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Price: 10.00
Industry: Medical - Biomedical and Genetics
With LOGICS Result Expected in September, Earlier Veldoreotide Program Should Not Be Overlooked; Reit Buy and $18 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Price: 25.00
Industry: Medical - Biomedical and Genetics
Focus Remains on Forthcoming LOGICS Data; With Patient Opportunity Highlighted by Market Assessment; Reit Buy and $18 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Price: 25.00
Industry: Medical - Biomedical and Genetics
3Q19 Preview Suggests Continued Forward Momentum; Reit Buy and $18 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Price: 10.00
Industry: Medical - Biomedical and Genetics
We View the Valuation Proposition as Attractive Heading Into LOGICS Readout
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Price: 10.00
Industry: Medical - Biomedical and Genetics
KOL Dinner on Emerging Therapies for Acromegaly
Provider: H.C. Wainwright & Co., Inc.
Price: 10.00
Industry: Medical - Biomedical and Genetics
Clarity on the Recorlev Timeline Lessens Risk Profile, in our View; Reit Buy and $18 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Price: 10.00
Industry: Medical - Biomedical and Genetics
New Phase 3 SONICS Data Analysis Presented in Cushing?s Syndrome; Reit Buy and $18 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Price: 10.00
Industry: Medical - Biomedical and Genetics
Regulatory Clarity and Potential for Additional Business Development May Continue to Drive Shares in 2019
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Price: 10.00
Industry: Medical - Biomedical and Genetics
A Timely Deal May Be De-risking as a Whole; Reit Buy and $18 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Price: 25.00
Industry: Medical - Biomedical and Genetics
Full Results Paint More Complete Efficacy Picture; Reit Buy and $18 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Price: 10.00
Industry: Medical - Biomedical and Genetics
A Step Closer to a Two-Pronged Rare Endocrine Franchise
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Price: 10.00
Industry: Medical - Biomedical and Genetics
Our Thoughts on the Upcoming SONICS Trial and KOL Feedback
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Price: 10.00
Industry: Medical - Biomedical and Genetics
Commercial Launch and Clinical Data in Combo With Underlying Business Strength Should Continue to Drive Value; Reit Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Price: 10.00